FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3115288071> ?p ?o ?g. }

• W3115288071 endingPage "16" @default.
• W3115288071 startingPage "16" @default.
• W3115288071 abstract "To present the interim findings from a national study investigating the safety and efficacy of convalescent plasma (CP) containing detectable IgG antibodies as a treatment strategy for severe coronavirus disease 2019 (COVID-19).An open label, two-arm, phase-II clinical trial conducted across 22 hospitals from Saudi Arabia. The intervention group included 40 adults (aged ≥18 years) with confirmed severe COVID-19 and the control group included 124 patients matched using propensity score for age, gender, intubation status, and history of diabetes and/or hypertension. Intervention group included those (a) with severe symptoms (dyspnea; respiratory rate, ≥30/min; SpO2, ≤93%, PaO2/FiO2 ratio, <300; and/or lung infiltrates >50% within 24-48 h), (b) requiring intensive care unit (ICU) care or (c) experiencing life-threatening conditions. The control group included confirmed severe COVID-19 patients of similar characteristics who did not consent for CP infusion or were not able to receive CP due to its nonavailability.The intervention group participants were infused 300 ml (200-400 ml/treatment dose) CP at least once, and if required, daily for up to 5 sessions, along with receiving the best standard of care. The control group only received the best standard of care.The primary endpoints were safety and ICU length of stay (LOS). The secondary endpoints included 30-day mortality, days on mechanical ventilation and days to clinical recovery.CP transfusion did not result in any adverse effects. There was no difference in the ICU LOS (median 8 days in both groups). The mortality risk was lower in the CP group: 13% absolute risk reduction (P = 0.147), hazard ratio (95% confidence interval): 0.554 (0.299-1.027; P = 0.061) by log-rank test. There was no significant difference in the days on mechanical ventilation and days to clinical recovery.CP containing detectable antibodies is a safe strategy and may result in a decrease in mortality in patients with severe COVID-19. The results of the completed trial with a larger study sample would provide more clarity if this difference in mortality is significant.ClinicalTrials.gov Identifier: NCT04347681; Saudi Clinical Trials Registry No.: 20041102." @default.
• W3115288071 created "2021-01-05" @default.
• W3115288071 creator A5005774563 @default.
• W3115288071 creator A5006011073 @default.
• W3115288071 creator A5022748817 @default.
• W3115288071 creator A5022751198 @default.
• W3115288071 creator A5022864260 @default.
• W3115288071 creator A5024084873 @default.
• W3115288071 creator A5030648853 @default.
• W3115288071 creator A5030690505 @default.
• W3115288071 creator A5040494879 @default.
• W3115288071 creator A5042814669 @default.
• W3115288071 creator A5042871448 @default.
• W3115288071 creator A5048119678 @default.
• W3115288071 creator A5048645158 @default.
• W3115288071 creator A5054579119 @default.
• W3115288071 creator A5054965741 @default.
• W3115288071 creator A5058456228 @default.
• W3115288071 creator A5059448504 @default.
• W3115288071 creator A5060795602 @default.
• W3115288071 creator A5061165667 @default.
• W3115288071 creator A5061716065 @default.
• W3115288071 creator A5062223414 @default.
• W3115288071 creator A5063627229 @default.
• W3115288071 creator A5070765444 @default.
• W3115288071 creator A5072288963 @default.
• W3115288071 creator A5074391726 @default.
• W3115288071 creator A5081165810 @default.
• W3115288071 creator A5082271053 @default.
• W3115288071 creator A5084754630 @default.
• W3115288071 creator A5086629044 @default.
• W3115288071 date "2021-01-01" @default.
• W3115288071 modified "2023-09-27" @default.
• W3115288071 title "Safety and Efficacy of Convalescent Plasma for Severe COVID-19: Interim Report of a Multicenter Phase II Study from Saudi Arabia" @default.
• W3115288071 cites W2225294925 @default.
• W3115288071 cites W3006252254 @default.
• W3115288071 cites W3008954191 @default.
• W3115288071 cites W3012893125 @default.
• W3115288071 cites W3013627131 @default.
• W3115288071 cites W3013742505 @default.
• W3115288071 cites W3013985547 @default.
• W3115288071 cites W3014168462 @default.
• W3115288071 cites W3014185271 @default.
• W3115288071 cites W3014853902 @default.
• W3115288071 cites W3015112391 @default.
• W3115288071 cites W3030097359 @default.
• W3115288071 cites W3032394272 @default.
• W3115288071 cites W3034286795 @default.
• W3115288071 cites W3036695043 @default.
• W3115288071 cites W3042890801 @default.
• W3115288071 cites W3047848658 @default.
• W3115288071 cites W3048907206 @default.
• W3115288071 cites W3049332674 @default.
• W3115288071 cites W3084261189 @default.
• W3115288071 cites W3085955680 @default.
• W3115288071 cites W3093711492 @default.
• W3115288071 doi "https://doi.org/10.4103/sjmms.sjmms_731_20" @default.
• W3115288071 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7839574" @default.
• W3115288071 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33519339" @default.
• W3115288071 hasPublicationYear "2021" @default.
• W3115288071 type Work @default.
• W3115288071 sameAs 3115288071 @default.
• W3115288071 citedByCount "14" @default.
• W3115288071 countsByYear W31152880712021 @default.
• W3115288071 countsByYear W31152880712022 @default.
• W3115288071 countsByYear W31152880712023 @default.
• W3115288071 crossrefType "journal-article" @default.
• W3115288071 hasAuthorship W3115288071A5005774563 @default.
• W3115288071 hasAuthorship W3115288071A5006011073 @default.
• W3115288071 hasAuthorship W3115288071A5022748817 @default.
• W3115288071 hasAuthorship W3115288071A5022751198 @default.
• W3115288071 hasAuthorship W3115288071A5022864260 @default.
• W3115288071 hasAuthorship W3115288071A5024084873 @default.
• W3115288071 hasAuthorship W3115288071A5030648853 @default.
• W3115288071 hasAuthorship W3115288071A5030690505 @default.
• W3115288071 hasAuthorship W3115288071A5040494879 @default.
• W3115288071 hasAuthorship W3115288071A5042814669 @default.
• W3115288071 hasAuthorship W3115288071A5042871448 @default.
• W3115288071 hasAuthorship W3115288071A5048119678 @default.
• W3115288071 hasAuthorship W3115288071A5048645158 @default.
• W3115288071 hasAuthorship W3115288071A5054579119 @default.
• W3115288071 hasAuthorship W3115288071A5054965741 @default.
• W3115288071 hasAuthorship W3115288071A5058456228 @default.
• W3115288071 hasAuthorship W3115288071A5059448504 @default.
• W3115288071 hasAuthorship W3115288071A5060795602 @default.
• W3115288071 hasAuthorship W3115288071A5061165667 @default.
• W3115288071 hasAuthorship W3115288071A5061716065 @default.
• W3115288071 hasAuthorship W3115288071A5062223414 @default.
• W3115288071 hasAuthorship W3115288071A5063627229 @default.
• W3115288071 hasAuthorship W3115288071A5070765444 @default.
• W3115288071 hasAuthorship W3115288071A5072288963 @default.
• W3115288071 hasAuthorship W3115288071A5074391726 @default.
• W3115288071 hasAuthorship W3115288071A5081165810 @default.
• W3115288071 hasAuthorship W3115288071A5082271053 @default.
• W3115288071 hasAuthorship W3115288071A5084754630 @default.
• W3115288071 hasAuthorship W3115288071A5086629044 @default.
• W3115288071 hasBestOaLocation W31152880711 @default.
• W3115288071 hasConcept C126322002 @default.

• next